A phase II evaluation of the combination of paclitaxel protein-bound and carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC).

@article{Allerton2006API,
  title={A phase II evaluation of the combination of paclitaxel protein-bound and carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC).},
  author={Jeffrey P. Allerton and Christopher T. Hagenstad and R. Timothy Webb and G. Bellingham Smith and Robert A. Birch and Timothy F. Goggins and Suresh Katakkar and Wagma Khan and Nilesh D. Mehta and F. Anthony Greco},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 18_suppl},
  pages={7127}
}
7127 Background: Abraxane (A) is a cremophor free, albumin-bound nanoparticle of paclitaxel (P) approved for the treatment of metastatic breast cancer. Belani et al. (JCO 21: 2933-2939, 2003) reported that P 100 mg/m2 days 1, 8 and 15 q 28 days with C AUC 6 on day 1 led to a 32% response rate in 132 patients (pts) with NSCLC. The median time to progression (TTP) was 35 weeks (wks) for stage IIIB and 29 wks for stage IV. METHODS This study was designed to determine if substituting A for P at… CONTINUE READING